Compare Incyte Corporation (INCY) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Banco Santander SA — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Banco Santander SA trades at $13.49 (market cap $192.86B). The key difference: Banco Santander SA is far larger — about 8.4× Incyte Corporation's market cap, and Banco Santander SA pays a 2.06% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Banco Santander SA for 55 Days on average.
| INCY | SAN | |
|---|---|---|
Market Cap | $22.85B | $192.86B |
Volume | 1,927,029 | 10,644,519 |
Sector | Health | Financials |
52-Week High | $129.93 | $15.05 |
52-Week Low | $83.80 | $9.65 |
Typical Hold Time | 33 Days | 55 Days |
Enterprise Value | $18.35B | $360.86B |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
Banco Santander (SAN) trades at $13.48, down 1.32% with bearish technical signals despite strong fundamentals. The stock shows mixed earnings performance with Q1 2026 beat but Q2 miss, while maintaining robust profitability with 26.25% net margin and 16.07% ROE. Recent developments include the completed Webster Financial acquisition expanding U.S. presence and record quarterly profits reported in Q2 2026.
SAN presents a value opportunity with reasonable P/E of 13.55 and strong analyst support (64% buy ratings), though negative cash flow trends and declining operating cash flow from $56.7B in 2021 to -$24.2B in 2024 raise concerns. The Webster integration execution and European banking sector volatility represent key near-term risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
